Details
Stereochemistry | ACHIRAL |
Molecular Formula | C25H30N8O4 |
Molecular Weight | 506.5569 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COCCNC1=CC(NC(=O)N2CCCC3=CC(CN4CCN(C)CC4=O)=C(C=O)N=C23)=NC=C1C#N
InChI
InChIKey=BHKDKKZMPODMIQ-UHFFFAOYSA-N
InChI=1S/C25H30N8O4/c1-31-7-8-32(23(35)15-31)14-18-10-17-4-3-6-33(24(17)29-21(18)16-34)25(36)30-22-11-20(27-5-9-37-2)19(12-26)13-28-22/h10-11,13,16H,3-9,14-15H2,1-2H3,(H2,27,28,30,36)
Molecular Formula | C25H30N8O4 |
Molecular Weight | 506.5569 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://clinicaltrials.gov/ct2/show/NCT02325739Curator's Comment: The description was created based on several sources, including
https://encrypted.google.com/patents/WO2015059668A1
Sources: https://clinicaltrials.gov/ct2/show/NCT02325739
Curator's Comment: The description was created based on several sources, including
https://encrypted.google.com/patents/WO2015059668A1
FGF-401 is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, FGF401 binds to and inhibits the activity of FGFR4, which leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase upregulated in certain tumor cells and involved in tumor cell proliferation, differentiation, angiogenesis, and survival. FGF-401 is an FGFR4 inhibitor in phase I/II clinical studies at Novartis for the treatment of positive FGFR4 and KLB expression solid tumors and hepatocellular carcinoma.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3973 Sources: https://encrypted.google.com/patents/WO2015059668A1 |
7.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02325739
Unknown
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://encrypted.google.com/patents/WO2015059668A1
The effect of compounds (FGF-401) on cell proliferation is assessed using HuH-7 hepatocellular carcinoma cells obtained from the Japanese Collection of Research Bioresources Cell Bank (Cat# JCRB0403) and cultured in the vendor-recommended medium (DMEM high glucose (Amimed Cat# 1 -26F01 -I), 10% foetal calf serum (Invitrogen Cat# 16140-071 ), 1 mM sodium pyruvate (Amimed Cat# 5-60F00-H), 1x Penicillin/Streptomycin (Amimed Cat# 4-01 F00-H)) at 37°C in a humidified 5% C02 incubator. Specifically, 5000 cells/well were seeded in 96-well tissue culture plates (TPP Cat# 92696) in a total media volume of 100 μΙ/well and increasing compound dilutions or DMSO were added 24 hours thereafter in triplicates. 72 hours after compound addition, cells were fixed by adding 25 [ Uwe\\ of 20% glutaraldehyde (Sigma Aldrich Cat# G400-4) and incubated for 10 minutes at room temperature. Cells were washed three times with H20, 200 [ Uwe\\ and stained with 100 [ Uwe\\ 0.05% methylene blue (ABCR GmbH Cat# AB1 17904) for 10 minutes at room temperature. Cells were washed 3 times with H20, 200 ML/well and then lysed by adding 200 ML/well of 3% HCI (Fluka Cat# 84422) for 30 minutes at room temperature with shaking. Optical density was measured at A650 nm.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:01:55 GMT 2023
by
admin
on
Sat Dec 16 10:01:55 GMT 2023
|
Record UNII |
M64JF6WMSA
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1708971-55-4
Created by
admin on Sat Dec 16 10:01:55 GMT 2023 , Edited by admin on Sat Dec 16 10:01:55 GMT 2023
|
PRIMARY | |||
|
118036971
Created by
admin on Sat Dec 16 10:01:55 GMT 2023 , Edited by admin on Sat Dec 16 10:01:55 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545293
Created by
admin on Sat Dec 16 10:01:55 GMT 2023 , Edited by admin on Sat Dec 16 10:01:55 GMT 2023
|
PRIMARY | |||
|
M64JF6WMSA
Created by
admin on Sat Dec 16 10:01:55 GMT 2023 , Edited by admin on Sat Dec 16 10:01:55 GMT 2023
|
PRIMARY | |||
|
10760
Created by
admin on Sat Dec 16 10:01:55 GMT 2023 , Edited by admin on Sat Dec 16 10:01:55 GMT 2023
|
PRIMARY | |||
|
100000181188
Created by
admin on Sat Dec 16 10:01:55 GMT 2023 , Edited by admin on Sat Dec 16 10:01:55 GMT 2023
|
PRIMARY | |||
|
C120102
Created by
admin on Sat Dec 16 10:01:55 GMT 2023 , Edited by admin on Sat Dec 16 10:01:55 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|